Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine when administered to healthy Japanese adults aged ≥50 years: An open-label trial

Documenti analoghi

• Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine compared to the 23-valent pneumococcal polysaccharide vaccine in elderly Japanese adults
  di: Shiramoto, Masanari, et al.
  Pubblicazione: (2015)
• Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in adults 50 to 65 years of age in India: An open-label trial
  di: Solanki, Bhagirath B., et al.
  Pubblicazione: (2017)
• Open-Label Trial of Immunogenicity and Safety of a 13-Valent Pneumococcal Conjugate Vaccine in Adults ≥50 Years of Age in Mexico
  di: Tinoco, Juan Carlos, et al.
  Pubblicazione: (2015)
• Immunogenicity and Safety of a 13-Valent Pneumococcal Conjugate Vaccine Coadministered with a Quadrivalent Influenza Vaccine in Adults 50 Years and Older Previously Vaccinated With 23-Valent Pneumococcal Polysaccharide Vaccine
  di: Baxter, Roger, et al.
  Pubblicazione: (2015)
• Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in HIV-infected individuals naive to pneumococcal vaccination
  di: Bhorat, As’ad E., et al.
  Pubblicazione: (2015)